- Report
- June 2026
- 181 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- June 2026
- 184 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- June 2026
- 181 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- June 2026
- 191 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- June 2026
- 187 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- June 2026
- 183 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- June 2026
- 198 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- June 2026
- 185 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- June 2026
- 183 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- June 2026
- 199 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- January 2026
- 199 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- January 2026
- 188 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- January 2026
- 191 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- January 2026
- 181 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- January 2026
- 191 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- January 2026
- 182 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- January 2026
- 182 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- January 2026
- 185 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- January 2026
- 198 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- January 2026
- 197 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP

Diabetic Retinopathy (DR) is a medical condition that affects the eyes of people with diabetes. It is caused by damage to the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. DR can lead to vision loss and blindness if left untreated.
Optical imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are used to diagnose and monitor DR. These technologies allow for early detection and treatment of DR, which can help to reduce the risk of vision loss.
In addition to imaging technologies, there are a number of treatments available for DR, including laser photocoagulation, intravitreal injections, and vitrectomy. These treatments can help to reduce the risk of vision loss and improve vision in those with DR.
The DR market is a rapidly growing market, driven by the increasing prevalence of diabetes and the need for early detection and treatment of DR.
Companies in the DR market include Carl Zeiss Meditec, Topcon Corporation, Optos, Nidek, and Heidelberg Engineering. Show Less Read more